Stress causes “ulcers and heartburn”, said Lex in the FT. “Now the treatment of these afflictions is causing anxiety for investors.”
Shares of GlaxoSmithKline, Sanofi and the new GSK spin-off, Haleon, all fell sharply last week – shedding tens of billions of dollars – as investors took fright over the reported carcinogenic risk posed by the over-the-counter drug Zantac. Damages, if awarded, could be as high as $45bn, according to Morgan Stanley. And since rights of the over-the-counter version of Zantac have been transferred repeatedly, “it is unclear where any liabilities might sit”.
The issue of whether Zantac (the brand name for a drug called ranitidine) generates a probable carcinogen called NDMA has been building in the background for years, said Julianna Tatelbaum on CNBC: the drug was formally pulled from shelves in 2020, but legal proceedings have focused minds. The first of more than 2,000 cases begins in the US this month.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The pharmas believe their legal position is strong, said Fierce Pharma. “The overwhelming weight of the scientific evidence supports the conclusion that there is no increased cancer risk,” stated GSK. Even if that risk is demonstrated, it will be “tough” to prove that the companies “knew of the danger and failed to warn customers” before withdrawing Zantac.
The litigation creates an awkward situation for GSK and the recently floated Haleon, said Alistair Osborne in The Times. If liability becomes an issue, it could mean “an unseemly legal dust-up between two companies that were in the same group four weeks ago”.
Precedent suggests investors should certainly remain wary, said Lex. The Bayer/Roundup weedkiller saga – which ultimately cost the German pharma at least $16bn – “shows it is easy to draw a line under claims prematurely”.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
What Trump's New York fraud conviction means for his business empireSpeed Read A New York judge has ordered many of Trump's companies to be placed into receivership and dissolved, but questions remain
-
'Poisonous'
Today's Newspapers A round-up of the headlines from the UK front pages
-
Drug could allow you to 'grow new teeth'
Tall Tales And other stories from the stranger side of life
-
Fixing the NHS workforce
The Explainer There are roughly 112,000 vacant posts in NHS England with nearly one in ten posts unfilled
-
The 'forever chemicals' in our water
PFAS compounds are used in thousands of products — and have been linked to numerous health risks. Should we be worried?
-
The dramatic rise of vaping in the UK
feature Increasing numbers of children are using e-cigarettes adding to the growing chorus of alarm over the potential impact on public health
-
The ‘dramatic’ rise of ADHD
feature Diagnoses of attention deficit hyperactivity disorder have risen sharply in the UK
-
Good health news: seven surprising medical discoveries made in 2023
In Depth A fingerprint test for cancer, a menopause patch and the shocking impacts of body odour are just a few of the developments made this year
-
The ubiquity of dangerous ultra-processed foods
feature Global consumption has been rising rapidly in recent decades – and the UK and US are leading consumers
-
Five good-news cancer breakthroughs in 2023
In Depth Cancer-sniffing ants, ‘Bond villain’ DNA, and vaccine trials are just a few exciting developments in cancer research this year
-
How gas hobs became America’s latest culture war
Talking Point Row caused by suggestion gas hobs might be banned on grounds of being a health hazard
